Identifying New Therapeutics

Eshelman professor secures secures $2.2 million to develop leukemia, lymphoma treatment.

Qisheng Zhang portrait

Eshelman professor secures secures $2.2 million to develop leukemia, lymphoma treatment.

UNC Eshelman School of Pharmacy Associate Professor Qisheng Zhang was recently awarded a $2,247,857 grant from the National Cancer Institute to study mutations in lymphomas and leukemias with the goal of identifying new therapeutics.

The four-year grant will support his work, “A high-throughput platform to identify selective allosteric inhibitors of the PLC-g isozymes.” Co-investigators on the study include Eshelman faculty John Sondek and Kenneth Pearce Jr.

“Our goal is to discover selective inhibitors to further understand how hyperactive PLC-g proteins drive cancer and ultimately to develop novel approaches to treat leukemias and lymphomas,” Zhang said.

Read the complete Carolina Story…Opens in new window


UNC Eshelman School of Pharmacy Funding Priorities

Readers Also Viewed...

Shawn Hingtgen and Jillian Perry

Treating the Untreatable

New research funded by a NIH grant seeks to combat one of the most treatment-resistant cancers

Rebeca Stiepel

Passion and Aptitude

Rebeca Stiepel received the 2022 Kathryne A. Brewington Graduate Research Award

Dr. David Drewry at the Genetic Medicine Building on the campus of UNC-Chapel Hill .

Collaborating for a Cure

Drug treatments for a rare form of cancer have eluded researchers for years. Work at the UNC Eshelman School of Pharmacy has scientists and survivors optimistic that big breakthroughs are within reach.

Two scientists look at test tubes

Fighting Future Pandemics

SAS Joins READDI in the Fight to Prevent Future Pandemics

Pharmacists practicing to administer a vaccine.

Future Pharmacists at the Ready

“We are preparing ourselves… to be key administers of this vaccine.”


Discovering Disease Treatments

Strengthening neuroscience research